Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response

Alessandra Iurlo, Umberto Gianelli, Alessandro Beghini, Orietta Spinelli, Nicola Orofino, Francesca Lazzaroni, Stefano Cambiaghi, Tamara Intermesoli, Alessandro Rambaldi, Agostino Cortelezzi

Research output: Contribution to journalArticle

Abstract

Activating mutations of KIT receptor tyrosine kinase have been reported in different neoplasms. The M541L KIT substitution (kitM541l) has been described to be associated with pediatric mastocytosis, to enhance growth rate of the affected cells and to confer higher sensitivity to imatinib therapy. We investigated the presence of kitM541l in five males with chronic eosinophilic leukemia, not otherwise specified (CEL, NOS), all negative for Platelet-derived growth factor-alpha (PDGFR) or PDGFRbeta abnormalities, which responded to imatinib therapy. To assess whether the mutation was constitutive or somatic in nature, we evaluated its presence analyzing either the neoplastic or normal cell population (epidermal cells or CD3-positive T lymphocytes). kitM541l substitution was found in 4 out of 5 patients and in all it was somatic in nature. All patients were treated with low dose imatinib (100 mg daily orally), achieving complete and persistent clinical and hematological remission (median follow-up 74 months). One patient relapsed after 50 months. Our study strongly suggests to search for the kitM541l in patients with CEL, NOS, negative for PDGFRalpha and PDGFRbeta abnormalities, to identify a subgroup of cases who may benefit from low dose imatinib therapy.

Original languageEnglish
Pages (from-to)4665-4670
Number of pages6
JournalOncotarget
Volume5
Issue number13
Publication statusPublished - 2014

Keywords

  • CEL-NOS
  • Chronic eosinophilic leukemia
  • Hypereosinophilic syndrome
  • KIT mutation
  • KIT541L

ASJC Scopus subject areas

  • Oncology
  • Medicine(all)

Fingerprint Dive into the research topics of 'Identification of kitM541l somatic mutation in chronic eosinophilic leukemia, not otherwise specified and its implication in low-dose imatinib response'. Together they form a unique fingerprint.

  • Cite this